The oxaliplatin restored by the GSH greatly suppressed the tumor progression and induced immunogenicity, while the released NLG9219 overcame the immunosuppressive tumor microenvironment by deactivating the IDO‐1 activity. This evidence concerns the gene IDO1 and neoplasm.